Dr. Vivian Tian

We are happy to announce the initiation of a multi-country (ex-China) Phase 3 Clinical Trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, in patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC) in the neoadjuvant/adjuvant setting.  The company has received approval from the Drugs Controller General of India (DCGI) to begin patient enrollment and dosing in the country. To know more about this announcement, please visit https://bit.ly/4mZHtC4

447

6 Kommentare

Tubulis GmbH: Developing a new generation of ADC therapies 🧬 Tubulis wants to improve the efficacy of cancer therapies by using antibody drug conjugates (ADCs). Three pipeline products are currently in clinical #development! 💬 ‘We are where we are today thanks in part to the commitment of German and European investors,’ says Dr Dominik Schumacher (CEO, #Tubulis)! Find the full case study here: https://lnkd.in/dBg3nx6E #bio #cancer #lifescience #impactlifesciences #vc #vcmagazin IZB - Innovation and Start-up Center Biotechnology Karin Hofelich #munich Trophic Communications #tech #health #innovation #investing #ADC #medicine Ludwig-Maximilians-Universität München Helmholtz Munich #casestudy #startup

138

🚀 FDA Novel Drug Approvals – 1H 2025 CDER approved 16 new drugs across oncology, pain, rare diseases, immunology, and infectious disease. Oncology & Rare Cancers: 1. Datopotamab deruxtecan (Datroway): ADC for metastatic HR+ HER2- breast cancer. 2. Treosulfan (Grafapex): Pre-transplant regimen for AML/MDS. 3. Mirdametinib (Gomekli): MEK1/2 inhibitor for neurofibromatosis type 1. 4. Vimseltinib (Romvimza): CSF1R inhibitor for tenosynovial giant cell tumor. 5. Avutometinib/Defactinib: KRAS-mutated recurrent low-grade serous ovarian cancer. 6. Telisotuzumab vedotin (Emrelis): c-Met ADC for NSCLC. 7. Taletrectinib (Ibtrozi): ROS1/pan-NTRK inhibitor for ROS1+ NSCLC. 8. Penpulimab: PD-1 mAb for nasopharyngeal carcinoma. Pain & Symptom Relief: - Suzetrigine (Journavx): Oral non-opioid analgesic (Nav1.8 inhibitor). Acoltremon (Tryptyr): TRPM8 activator for dry eye syndrome. Rare & Genetic Diseases: 1. Fitusiran (Qfitlia): Anti-thrombin siRNA for hemophilia A/B prophylaxis. 2. Nipocalimab (Imaavy): FcRn mAb for generalized myasthenia gravis. 3. Garadacimab (Andembry): Factor XII mAb for hereditary angioedema prophylaxis. 4. Atrasentan (Vanrafia): Endothelin A antagonist for IgA nephropathy. Infectious Disease: 5. Gepotidacin (Blujepa): DNA gyrase/topoisomerase IV inhibitor for cystitis & gonorrhea. 6. Clesrovimab (Enflonsia): RSV mAb for infant passive immunity. Credit/Source: Chris De Savi #biotech #biopharma #pharmaceuticals #pharma

457

13 Kommentare

How can you take the first step in managing non-small cell lung cancer (NSCLC) - the most common type of #LungCancer?    #BiomarkerTesting plays a crucial role in providing deeper insights into a lung cancer diagnosis.   HER2 (ERBB2) mutations are rare but important in NSCLC. They can be identified through next-generation sequencing.     Learn more about HER2 mutations and research: https://lnkd.in/d3T8BYgM   #LifeForward #PersonalizedMedicine

463

3 Kommentare

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Monte Rosa Therapeutics' CEO Markus Warmuth updates us on the company's progress in developing molecular glue degraders. The company, which recently had a paper earn a spot on the cover of Science, is progressing ahead with both I&I and oncology indications. Dr. Warmuth walks us through the pipeline progress and overall strategy of finding and pursuing targets. Full video: https://lnkd.in/gvcR9Pj9 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills | Genezen

215

2 Kommentare

Cereno Scientific (STO: CRNO-B) is a clinical-stage #biotech focused on developing innovative #treatments for rare indications in the #cardiovascular and #pulmonary spaces. Its pipeline is led by CS1 and CS014, HDAC inhibitors with disease-modifying potential in pulmonary arterial hypertension and idiopathic pulmonary fibrosis, respectively. Both candidates are backed by promising clinical data and are gearing up for more advanced-stage clinical studies (Phase IIb for CS1 and Phase II for CS014) in H126. A third asset, CS585, a prostacyclin receptor agonist, is currently under preclinical evaluation for cardiovascular indications. In this interview, we speak with Sten R. Sörensen, CEO of Cereno Scientific, to discuss developments in the company’s asset pipeline, including the recent FDA fast track designation for CS1 and the positive Phase I results for CS014. Mr Sörensen also provides further insight into the ongoing preparatory work for the upcoming Phase IIb trial for CS1 in H126,as well as the plans for CS014. We cover CS585’s progress as it is expected to enter the clinic in 2027. He also shares his thoughts on the company’s strategic approach to financing the upcoming studies, and potential partnering discussions. 🎥 Watch the full video below 👇 Jyoti Prakash, CFA

46

Good news for Bioxodes and its treatment for haemorrhagic stroke. Following promising results from the Phase 2a clinical trial, Bioxodes can move on to a new phase and aims to bring the product to market before 2030. Marc Dechamps, Chief Executive Officer of Bioxodes: “We are in discussions with prospective investors and partners to support the launch of a potentially registrational Phase 2b trial of BIOX-101 to treat intracerebral hemorrhage. Given the high unmet medical need in ICH and Orphan Drug Designations for BIOX-101 in both the U.S. and EU, we believe this breakthrough therapeutic candidate can come to market as early as 2030.” 👉 Read the full release: https://lnkd.in/eyXTrXY9 👉 Read the full article: https://lnkd.in/e3EprXvY

190

9 Kommentare